Clearmind Medicine advances clinical pipeline as Yale IRB approval unlocks new patient recruitment phases for CMND-100
Executive summary: Clearmind Medicine received Yale IRB approval to begin recruiting patients for Parts B and C of its CMND-100 Phase I/II trial. The approval follows positive safety results, moving the company closer to evaluating the efficacy of its neuroplastogen for neuropsychiatric conditions.
Who is involved: Clearmind Medicine Inc. (Nasdaq: CMND) and Yale Institutional Review Board (IRB).
Likely next: Commencement of active patient enrollment for the specified trial segments.
Clearmind Medicine has secured Institutional Review Board (IRB) approval from Yale to proceed with critical recruitment for its CMND-100 trial. This follows previously reported positive safety data for the non-hallucinogenic psychedelic-derived neuroplastogen. The move transitions the Phase I/II study into more advanced stages (Parts B and C), a key milestone in clinical development.
What's next — scenarios
Base Case: Successful recruitment and efficacy data (50%)
Increased investor confidence and potential path toward Phase III
- Steady patient enrollment rates in Parts B and C
- Positive interim efficacy readout
Downside Case: Recruitment delays or safety signals (30%)
Cash burn increases and potential clinical hold
- Slow recruitment due to stringent protocol
- Adverse events in the expanding cohort
Upside Case: Accelerated Phase II completion (20%)
Early partnership discussions with major pharmaceutical players
- Rapid enrollment exceeding projections
- Strong safety profile in expanded cohorts
What to watch
- Announcements regarding patient enrollment milestones for CMND-100
- Interim clinical data readouts from Parts B and C
Timeline
- — Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial (GlobeNewswire)
- — West Cancer Center Receives IRB Approval for IceCure Study (PR Newswire)
- — Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Study (GlobeNewswire)
Analysis — what this means
Likely next events
- Commencement of patient recruitment (Post-IRB approval)
Sectors affected
- Neuropsychiatric therapeutics
- Psychedelic-derived medicine
Regulatory implications
- Compliance with Yale IRB ethical standards for human subjects
Historical parallels
- Medicus Pharma Phase 2 IRB approval (2026)
- West Cancer Center IRB approval for IceCure (2026)
Key entities
Sources
- Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial — GlobeNewswire
- Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Study — GlobeNewswire
- West Cancer Center Receives IRB Approval for IceCure Study — PR Newswire